Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GALMED PHARMACEUTICALS LTD.

(GLMD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
2.72(c) 2.72(c) 2.73(c) 2.78(c) 2.75(c) Last
105 188 27 508 28 537 48 542 27 972 Volume
+3.03% -0.00% +0.37% +1.83% -1.08% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 - - -
Net income 2021 -35,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,98x
Yield 2021 -
Sales 2022 - - -
Net income 2022 -42,2 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,03x
Yield 2022 -
Capitalization 69,0 M 69,0 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 21
Free-Float 86,0%
More Financials
Company
Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis). 
More about the company
Ratings of Galmed Pharmaceuticals Ltd.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about GALMED PHARMACEUTICALS LTD.
10/12GALMED PHARMACEUTICALS : Results of Galmed's Phase 2b ARREST Trial of Aramchol Published i..
PU
10/11GALMED PHARMACEUTICALS : Results of Galmed's Phase 2b ARREST Trial of Aramchol Published i..
PR
10/11Galmed Pharmaceuticals Ltd. Announces One-Year Results of Global Phase 2b Randomized Pl..
CI
09/20GALMED PHARMACEUTICALS LTD.(NASDAQCM : GLMD) dropped from S&P Global BMI Index
CI
08/19GALMED PHARMACEUTICALS : Announces Publication in “The Journal of Autoimmunity&rdquo..
PU
08/16GALMED PHARMACEUTICALS : MHRA Agrees with Galmed's Plan to use Aramchol meglumine in the R..
PU
08/16MHRA Agrees with Galmed's Plan to Use Aramchol Meglumine in the Randomized Double-Blind..
CI
08/05GALMED PHARMACEUTICALS : Q2 Earnings Snapshot
AQ
08/05Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter Ended June ..
CI
08/02GALMED PHARMACEUTICALS : Secures FDA OK to Use Aramchol Meglumine in Phase 3 Armor Trial
MT
08/02GALMED PHARMACEUTICALS : FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Ra..
PU
08/02GALMED PHARMACEUTICALS : FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Ra..
PR
08/02FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized Double-Blind ..
CI
08/02Galmed Shares Up After FDA Agrees With Plan on Study
DJ
07/19GALMED PHARMACEUTICALS : Form 6-K)
PU
More news
News in other languages on GALMED PHARMACEUTICALS LTD.

- No features available -

More news
Analyst Recommendations on GALMED PHARMACEUTICALS LTD.
More recommendations
Chart GALMED PHARMACEUTICALS LTD.
Duration : Period :
Galmed Pharmaceuticals Ltd. Technical Analysis Chart | GLMD | IL0011313900 | MarketScreener
Technical analysis trends GALMED PHARMACEUTICALS LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 2,75 $
Average target price 17,00 $
Spread / Average Target 518%
EPS Revisions
Managers and Directors
Allen Baharaff Chairman, President & Chief Executive Officer
Yohai Stenzler Chief Financial Officer
Liat Hayardeny Chief Scientific Officer
Guy Nehemya Chief Operating Officer
Shmuel Nir Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GALMED PHARMACEUTICALS LTD.-11.58%69
GILEAD SCIENCES, INC.16.08%84 795
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156